Biomarkers for the diagnosis of endometriosis

A purpose and specific technology, applied in the field of medical diagnosis, to facilitate staining, avoid contamination, and improve sensitivity

Active Publication Date: 2020-05-12
北京昂科未来医疗器械有限公司
View PDF7 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Previously reported EM biomarkers are mostly glycoproteins, cytokines, non-coding RNA and other molecules, which can only reflect the impact of the disease on certain aspects of the body

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Biomarkers for the diagnosis of endometriosis
  • Biomarkers for the diagnosis of endometriosis
  • Biomarkers for the diagnosis of endometriosis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0059] Example 1: Collection of endometrial cell samples

[0060] A total of 59 patients were recruited. Forty-four patients underwent surgical treatment at Peking University People's Hospital from October 2015 to July 2016 due to ovarian tumors detected by ultrasound. According to laparoscopic and pathological diagnosis, 19 cases were EM, 25 cases were non-EM (including 16 cases of other benign ovarian tumors, 4 cases of ovarian cancer, and 5 cases of other benign ovarian tumors complicated with adenomyosis (Table 1). Among them, the age of EM group was 33.4±7.8 years (22-45 years old), BMI was 21.5±2.8 (17.4-26.7), 13 cases (68.4%) had dysmenorrhea, 13 cases (68.4%) were in proliferative stage, 6 cases (31.6% %) was in the secretory phase, and the EM stage was judged according to rAFS (revised Classification of the American Society of Reproductive Medicine). Among them, 5 cases (26.3%) were in stage I-II, and 14 cases (73.7%) were in stage III-IV. In addition, 15 cases were...

Embodiment 2

[0064] Example 2: Detection of endometrial cells

[0065] The cell suspension collected in Example 1 was injected into the microfluidic chip (Lv P et al. , 2013), endometrial cells were captured by micropillars arranged in a spatial gradient. The endometrial cells were identified in the chip by immunofluorescent staining. Inject 4% paraformaldehyde into the chip to fix the cells for 20 minutes. After washing with PBS, pass through 0.1% Triton X-100 (Sigma) for 10 minutes to rupture the membrane. After washing with PBS, block with 10% bovine serum (Wisent) for 20 minutes, and then inject Primary antibody and DAPI (Life Technologies), incubated overnight at 4°C, washed with PBS, injected with secondary antibody and incubated at room temperature. Images were observed and collected using a fluorescent inverted microscope (DM IL LED, Leica Microsystems). The primary antibodies were used as follows: pre-stained PE anti-Vimentin mouse monoclonal antibody (1:100, Abcam), pre-stain...

Embodiment 3

[0073] Example 3: The value of CECs in auxiliary diagnosis of EM

[0074] In order to evaluate whether CECs can be used as EM biomarkers for auxiliary diagnosis, we calculated the sensitivity and specificity of CECs when compared with other benign tumor groups and healthy controls, and compared with serum CA125 (>35U / mL defined as test positive) were compared ( figure 2 ).

[0075] Serum CA125 assays from the same subjects in Example 1 were used as controls. Serum CA125 was quantitatively detected by the Laboratory Department of Peking University People's Hospital using the electrochemiluminescence method, and using the Carbohydrate Antigen 125 Detection Kit (Roche Diagnostics) in accordance with the operating procedures given by the manufacturer. The detection system is Cobase 411x electrochemiluminescence automatic immunoassay system (Roche Diagnostics)

[0076] Statistical analysis was performed with SPSS22 software. Normality testing of the data was performed by the K...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to a biomarker, a kit and a method for diagnosing endometriosis, and concretely provides a use of a monoclonal antibody binding to a specific antigen on a circulating endometrialcell in the preparation of the kit for diagnosing endometriosis.

Description

technical field [0001] The present application relates to the field of medical diagnosis, in particular to biomarkers, kits and methods for diagnosing endometriosis. Background technique [0002] Endometriosis (EM) refers to the presence of active endometrial glands or stroma anywhere outside the uterine cavity. Currently, EM affects more than 10% of women of reproductive age. Ectopic endometrial tissue can appear in the peritoneum, pelvic organs, and even distant organs such as the lung and brain, often causing infertility, pelvic pain, and mass. Infertility, pelvic pain and high medical costs seriously affect the quality of life of women in the long process of patients seeking diagnosis and treatment. Therefore, it is important to detect and manage endometriosis at an early stage. However, due to the atypical clinical symptoms of some patients, EM must be diagnosed by invasive laparoscopy to find heterotopic lesions, resulting in an average delay of 7-11 years in diagno...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): G01N33/68G01N33/577G01N33/574
CPCG01N33/57449G01N33/577G01N33/6893G01N2333/4712G01N2333/4742G01N2333/72G01N2333/723G01N2800/364
Inventor 昌晓红祝洪澜崔恒陈颖程洪艳马瑞琼叶雪
Owner 北京昂科未来医疗器械有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap